Epoch 9: Pharma Business Model Dead on the Vine?
R&D Investment Trends, Strategy, Breakthrough Products
Welcome to the 33 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 1099 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:
Hello Avatar! Welcome back for another week of biotech analysis. We are now operating under a hybrid subscription model where the Sunday update has moved under the paywall - a BIG THANK YOU to those that have joined. The Thursday market update will continue to remain free. The more forward looking content, the insider insights, and market data you need to really assess what is happening in the world of biotech will shift to Sundays.
This week we are super excited to dig into the recent Global Trends in 2023 report from Iquiva. It is a beast and way too long for us to run through in one newsletter. We will break this up into three separate discussions with today being the first part of that dialog. The discussion today will cover many topics including, R&D investment, business transactions, clinical development, key therapeutic areas, and delivery of breakthrough biotech products. The last topic was eye opening to us as it put some data behind the statement that pharma is not producing innovative products. Much more detail below, we promise you will leave today with a number of thought provoking takeaways to discuss with your colleagues.
Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
Go forward we will be making announcements regarding significant public biotech trading opportunities via substack ALERT special posts. This will focus primarily on the major market moving biotech events and will likely be centered around data readouts from the major scientific conferences. We will not offer trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely drive stock prices +/-100% in either direction. Be sure to SUBSCRIBE to not miss.
Enough shilling for the day, lots to cover this week, let's get started!
Keep reading with a 7-day free trial
Subscribe to BowTiedBiotech to keep reading this post and get 7 days of free access to the full post archives.